A clinical double-blind study of flumazenil, antagonist of benzodiazepines, in loco-regional anesthesia.
Flumazenil has been studied for antagonism of the residual sedative effect of midazolam administered as a complement of loco-regional anesthesias. Highly significant differences appeared between the patients receiving placebos and those receiving flumazenil, showing a quick suppression of the lasting sedative effects of midazolam. At the dosage of 1 mg, flumazenil seemed to have a more efficient and complete effect than the 0.5 mg dosage. Tolerance to flumazenil was excellent with the exception of one case of agitation and disorientation, in a patient chronic consumer of benzodiazepines thus this could be considered as a deprivation syndrome. In conclusion, flumazenil should certainly have a place in the pharmacological stores of the anesthesiologist.
Bianchi
G
G
Institut Médical de Traumatologie, Loveral.
Stenier
P
P
D000368:Aged; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D005442:Flumazenil / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008874:Midazolam / Q000037:antagonists & inhibitors*; D008875:Middle Aged; D011229:Preanesthetic Medication; D011963:Receptors, GABA-A / Q000187:drug effects
D011963:Receptors, GABA-A; D005442:Flumazenil; D008874:Midazolam